Indenix Pharmaceuticals Inc., a biopharmaceutical company, works to develop, test and market products directed primarily at infectious and viral diseases in the United States and Europe. The company has been having solid successes with a full pipeline of products.

Although the company focuses a majority of its efforts on hepatitis C targeted products, it does have a rather interesting pipeline of products in development. This pipeline ranges from fully licensed hepatitis b products (to Novartis Pharma AG) and human immunodeficiency products (to GlaxoSmithKline), to Protease Inhibitors which are currently in the discovery stage. From an overall perspective, the company does appear to be in a fairly well developed place at the moment with all facets of development and marketing working in tandem.

What is perhaps most interesting with regard to ownership of the company is who and how much. Novartis holds the majority of outstanding stock with only 19 insiders involved. The remainder of stock issued is found in the hands of institutional investors and mutual funds. With this in mind it can also be mentioned that little selling is occurring indicating the stability and consistency found within the company. Investors see where and how the company is progressing and the likelihood of regular product development over time. They also see a quick and smooth transition to a license and marketing arm in Novartis.

There were two recent sales of stock by larger holders although these sales can likely be explained away due to issues the holders are currently dealing with. The world of Big Pharma is often characterized as fast plays with product moving through the FDA approvals process. Pharma is rarely referred to as a stable and consistent revenue producer over time where development periods are often represented by lower earning followed by blasts of solid earnings as products hit the market. Indenix Pharmaceuticals has a stable licensing base of revenue in place and product well on its way to approvals. If one is interested in a stable investment that will likely pay consistently over time, Indenix may be worth a look.